James W. Mier
Associate Professor of Medicine
Medicine
Beth Israel Deaconess Medical Center
United States of America
Biography
Dr. Mier is Director of Laboratory Research for the Biologics Therapy Program. His clinical and research interests include kidney cancer and melanoma. His current research efforts are focused on the mechanisms by which renal cell carcinomas become resistant to various targeted therapies including VEGF-R antagonists, the development of novel agents that block the PI3-kinase/mTOR pathway in renal cancer, and the role of HDM2 as a therapeutic target in melanoma and renal cell carcinoma. Board certified in Internal Medicine and Medical Oncology, Dr. Mier earned his medical degree from Indiana University School of Medicine, completed his internship and residency at Emory University Affiliated Hospitals and Atlanta VA Hospital and received his oncology training at the Medicine branch, National Cancer Institute, Bethesda, MD. He is an Associate Professor of Medicine at Harvard Medical School.
Research Interest
Melanoma; Renal Cell Cancer
Publications
-
Wang W, Erbe AK, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S. Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunology, Immunotherapy. 2016 Dec 1;65(12):1523-32.
-
Erbe AK, Wang W, Goldberg J, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC. FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 2017 May 1;23(9):2159-68.
-
Sarantopoulos J, Mita AC, He A, Wade JL, Hsueh CT, Morris JC, Lockhart AC, Quinn DI, Hwang J, Mier J, Zhang W. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study. Cancer chemotherapy and pharmacology. 2017 Feb 1;79(2):339-51.
